

- Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2011;144:646–674.
- Risk JM, Field EA, Field JK, et al. Tylosis oesophageal cancer mapped. *Nat Genet* 1994;8:319–321.
- Orloff M, Peterson C, He X, et al. Germline mutations in MSRI, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. *JAMA* 2011;306:410–419.
- Su Z, Gay LJ, Strange A, et al. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. *Nat Genet* 2012;44:1131–1136.
- Levine DM, Ek WE, Zhang R, et al. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. *Nat Genet* 2013;45:1487–1493.
- al-Kasspooles M, Moore JH, Orringer MB, et al. Amplification and overexpression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. *Int J Cancer* 1993;54:213–219.
- Torzewski M, Sarbia M, Verreet P, et al. The prognostic significance of epidermal growth factor receptor expression in squamous cell carcinomas of the oesophagus. *Anticancer Res* 1997;17:3915–3919.
- Inada S, Koto T, Futami K, et al. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). *Surg Today* 1999;29:493–503.
- Rusch V, Mendelsohn J, Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. *Cytokine Growth Factor Rev* 1996;7:133–141.
- Jankowski J, McMenemin R, Hopwood D, et al. Abnormal expression of growth regulatory factors in Barrett's oesophagus. *Clin Sci (Lond)* 1991;81:663–668.
- Yoshida K, Kuniyasu H, Yasui W, et al. Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha. *J Cancer Res Clin Oncol* 1993;119:401–407.
- Jankowski J, Hopwood D, Wormsley KG. Flow-cytometric analysis of growth-regulatory peptides and their receptors in Barrett's oesophagus and oesophageal adenocarcinoma. *Scand J Gastroenterol* 1992;27:147–154.
- Brito MJ, Filipe MI, Linehan J, et al. Association of transforming growth factor alpha (TGFA) and its precursors with malignant change in Barrett's epithelium: biological and clinical variables. *Int J Cancer* 1995;60:27–32.
- Yacoub L, Goldman H, Odze RD. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. *Mod Pathol* 1997;10:105–112.
- Itakura Y, Sasano H, Shiga C, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma: an immunohistochemical study correlated with clinicopathologic findings and DNA amplification. *Cancer* 1994;74:795–804.
- Hickey K, Grehan D, Reid IM, et al. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. *Cancer* 1994;74:1693–1698.
- Kitagawa Y, Ueda M, Ando N, et al. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. *Clin Cancer Res* 1996;2:909–914.
- Deshpande A, Sicinski P, Hinds PW. Cyclins and CDKs in development and cancer: a perspective. *Oncogene* 2005;24:2909–2915.
- Arber N, Lightdale C, Rotterdam H, et al. Increased expression of the cyclin D1 gene in Barrett's esophagus. *Cancer Epidemiol Biomarkers Prev* 1996;5:457–459.
- Roncagli M, Bosari S, Marchetti A, et al. Cell cycle-related gene abnormalities and product expression in esophageal carcinoma. *Lab Invest* 1998;78:1049–1057.
- Shamma A, Doki Y, Shiozaki H, et al. Cyclin D1 overexpression in esophageal dysplasia: a possible biomarker for carcinogenesis of esophageal squamous cell carcinoma. *Int J Oncol* 2000;16:261–266.
- Sarbia M, Bektas N, Muller W, et al. Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus. *Cancer* 1999;86:2597–2601.
- Barbash O, Zamfirova P, Lin DI, et al. Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. *Cancer Cell* 2008;14(1):68–78.
- Wong DJ, Barrett MT, Stoger R, et al. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. *Cancer Res* 1997;57:2619–2622.
- Klump B, Hsieh CJ, Holzmann K, et al. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. *Gastroenterology* 1998;115:1381–1386.
- Xing EP, Nie Y, Wang LD, et al. Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. *Carcinogenesis* 1999;20:77–84.
- Maesawa C, Tamura G, Nishizuka S, et al. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. *Cancer Res* 1996;56:3875–3878.
- Boynton RF, Huang Y, Blount PL, et al. Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. *Cancer Res* 1991;51:5766–5769.
- Coppola D, Schreiber RH, Mora L, et al. Significance of Fas and retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma. *Ann Surg Oncol* 1999;6:298–304.
- Ikeguchi M, Oka S, Gomyo Y, et al. Clinical significance of retinoblastoma protein (pRB) expression in esophageal squamous cell carcinoma. *J Surg Oncol* 2000;73:104–108.
- Joerger AC, Ang HC, Veprintsev DB, et al. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. *J Biol Chem* 2005;280:16030–16037.
- Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. *Nat Med* 2004;10:789–799.
- Sengupta S, Harris CC. p53: traffic cop at the crossroads of DNA repair and recombination. *Nat Rev Mol Cell Biol* 2005;6:44–55.
- Hamelin R, Flejou JF, Muzeau F, et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. *Gastroenterology* 1994;107:1012–1018.
- Ramel S, Reid BJ, Sanchez CA, et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. *Gastroenterology* 1992;102:1220–1228.
- Younes M, Lebovitz RM, Lechago LV, et al. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. *Gastroenterology* 1993;105:1637–1642.
- Casson AG, Mukhopadhyay T, Cleary KR, et al. p53 gene mutations in Barrett's epithelium and esophageal cancer. *Cancer Res* 1991;51:4495–4499.
- Gaur D, Arora S, Mathur M, et al. High prevalence of p53 gene alterations and protein overexpression in human esophageal cancer: correlation with dietary risk factors in India. *Clin Cancer Res* 1997;3:2129–2136.
- Kato H, Yoshikawa M, Miyazaki T, et al. Expression of p53 protein related to smoking and alcoholic beverage drinking habits in patients with esophageal cancers. *Cancer Lett* 2001;167:65–72.
- Lam KY, Tsao SW, Zhang D, et al. Prevalence and predictive value of p53 mutation in patients with oesophageal squamous cell carcinomas: a prospective clinicopathological study and survival analysis of 70 patients. *Int J Cancer* 1997;74:212–219.
- Taniere P, Martel-Planche G, Saurin JC, et al. TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe. *Br J Cancer* 2001;85:721–726.
- Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, et al. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. *Cancer* 1998;83:7–18.
- Koyanagi K, Ozawa S, Ando N, et al. Clinical significance of telomerase activity in the non-cancerous epithelial region of esophageal squamous cell carcinoma. *Br J Surg* 1999;86:674–679.
- Morales CP, Lee EL, Shay JW. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. *Cancer* 1998;83:652–659.
- Opitz OG, Suliman Y, Hahn WC, et al. Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism. *J Clin Invest* 2001;108(5):725–732.
- Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. *Trends Biochem Sci* 1999;24:73–76.
- Swami S, Kumble S, Triadafilopoulos G. E-cadherin expression in gastro-esophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study. *Am J Gastroenterol* 1995;90:1808–1813.
- Takeo S, Noguchi T, Fumoto S, et al. E-cadherin expression in patients with esophageal squamous cell carcinoma: promoter hypermethylation, Snail overexpression, and clinicopathologic implications. *Am J Clin Pathol* 2004;122:78–84.
- Okawa T, Michaylira CZ, Kalabis J, et al. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. *Genes Dev* 2007;21:2788–2803.
- Opitz OG, Harada H, Suliman Y, et al. A mouse model of human oral-esophageal cancer. *J Clin Invest* 2002;110:761–769.
- Stairs DB, Bayne LJ, Rhoades B, et al. Deletion of p120-catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene. *Cancer Cell* 2011;19:470–483.
- Siglin JC, Khare L, Stoner GD. Evaluation of dose and treatment duration on the esophageal tumorigenicity of N-nitrosomethylbenzylamine in rats. *Carcinogenesis* 1995;16:259–265.
- Xu X, LoCicero J 3rd, Macri E, et al. Barrett's esophagus and associated adenocarcinoma in a mouse surgical model. *J Surg Res* 2000;88:120–124.
- Quante M, Bhagat G, Abrams JA, et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. *Cancer Cell* 2012;21:36–51.
- Wang X, Ouyang H, Yamamoto Y, et al. Residual embryonic cells as precursors of a Barrett's-like metaplasia. *Cell* 2011;145:1023–1035.

56. Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. *Nat Genet* 2009;41:1238–1242.
57. Lin L, Bass AJ, Lockwood WW, et al. Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma. *Proc Natl Acad Sci USA* 2012;109:4251–4256.
58. Dulak AM, Stojanov P, Peng S, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. *Nat Genet* 2013;45:478–486.
59. Zangheri G, Di Gregorio C, Sacchetti C, et al. Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. *Cancer* 1990;66:2047–2051.
60. Mecklin JP, Nordling S, Saario I. Carcinoma of the stomach and its heredity in young patients. *Scand J Gastroenterol* 1988;23:307–311.
61. Gorer P. Genetic interpretation of studies on cancer in twins. *Ann Eugen* 1938;8:219.
62. Lee FI. Carcinoma of the gastric antrum in identical twins. *Postgrad Med J* 1971;47:622–624.
63. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. *Nature* 1998;392:402–405.
64. Gayther SA, Goringe KL, Ramus SJ, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. *Cancer Res* 1998;58:4086–4089.
65. Yoon KA, Ku JL, Yang HK, et al. Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. *J Hum Genet* 1999;44:177–180.
66. Shimura K, Kohno T, Takahashi M, et al. Familial gastric cancer: clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. *Carcinogenesis* 1999;20:1127–1131.
67. Pharoah PD, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. *Gastroenterology* 2001;121:1348–1353.
68. Lewis FR, Mellinger JD, Hayashi A, et al. Prophylactic total gastrectomy for familial gastric cancer. *Surgery* 2001;130:612–617.
69. Majewski IJ, Kluijft I, Cats A, et al. An  $\alpha$ -E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. *J Pathol* 2013;229:621–629.
70. Rustgi AK. The genetics of hereditary colon cancer. *Genes Dev* 2007;21:2525–2538.
71. El Omar EM, Rabkin CS, Gammon MD, et al. Increased risk of non-cardiac gastric cancer associated with proinflammatory cytokine gene polymorphisms. *Gastroenterology* 2003;124:1193–1201.
72. Billington BP. Gastric cancer relationships between blood groups, site, and epidemiology. *Lancet* 1956;2:859–862.
73. Buckwalter JA, Wholwend CB, Colter DC. The association of the ABO blood groups to gastric carcinoma. *Surg Gynecol Obstet* 1957;104:176–179.
74. Borén T, Falk P, Roth KA, et al. Attachment of *Helicobacter pylori* to human gastric epithelium mediated by blood group antigens. *Science* 1993;262:1892–1895.
75. Silva F, Carvalho F, Peixoto A, et al. MUC1 polymorphism confers increased risk for intestinal metaplasia in a Colombian population with chronic gastritis. *Eur J Hum Genet* 2003;11:380–384.
76. Lee HS, Chang MS, Yang HK, et al. Epstein-Barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein-Barr virus-negative carcinoma. *Clin Cancer Res* 2004;10:1698–1705.
77. Kim SJ, Bang YJ, Park JC, et al. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. *Proc Natl Acad Sci U S A* 1994;91:8772–8776.
78. Yamamoto H, Sawai H, Perucho M. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. *Cancer Res* 1997;57:4420–4426.
79. Yin J, Kong D, Wang S, et al. Mutation of hMSH3 and hMSH6 mismatch repair genes in genetically unstable human colorectal and gastric carcinomas. *Hum Mutat* 1997;10:474–478.
80. Souza RF, Appel R, Yin J, et al. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. *Nat Genet* 1996;14:255–257.
81. Souza RF, Yin J, Smolinski KN, et al. Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors. *Cancer Res* 1997;57:2350–2353.
82. Seruca R, Santos NR, David L, et al. Sporadic gastric carcinomas with microsatellite instability display a particular clinicopathologic profile. *Int J Cancer* 1995;64:32–36.
83. dos Santos NR, Seruca R, Constanca M, et al. Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. *Gastroenterology* 1996;110:38–44.
84. Hollstein M, Shomer B, Greenblatt M, et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. *Nucleic Acids Res* 1996;24:141–146.
85. Suzuki H, Itoh F, Toyota M, et al. Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. *Int J Cancer* 1999;83:309–313.
86. Toyota M, Ahuja N, Suzuki H, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. *Cancer Res* 1999;59:5438–5442.
87. Ascano JJ, Moskaluk CA, Harper JC, et al. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. *Mod Pathol* 2001;14:942–949.
88. Grady WM, Willis J, Guilford PJ, et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. *Nat Genet* 2000;26:16–17.
89. Taketo MM. Wnt signaling and gastrointestinal tumorigenesis in mouse models. *Oncogene* 2006;25:7522–7530.
90. Fox JG, Dangler CA, Whary MT, et al. Mice carrying a truncated Apc gene have diminished gastric epithelial proliferation, gastric inflammation, and humoral immunity in response to *Helicobacter felis* infection. *Cancer Res* 1997;57:3972–3978.
91. Teng Y, Sun AN, Pan XC, et al. Synergistic function of Smad4 and PTEN in suppressing forestomach squamous cell carcinoma in the mouse. *Cancer Res* 2006;66:6972–6981.
92. Watson SA, Grabowska AM, El-Zaatari M, et al. Gastrin—active participant or bystander in gastric carcinogenesis? *Nat Rev Cancer* 2006;6:936–946.
93. Wang TC, Dangler CA, Chen D, et al. Synergistic interaction between hypergastrinemia and *Helicobacter* infection in a mouse model of gastric cancer. *Gastroenterology* 2000;118:36–47.
94. Rogers AB, Taylor NS, Whary MT, et al. *Helicobacter pylori* but not high salt induces gastric intraepithelial neoplasia in B6129 mice. *Cancer Res* 2005;65:10709–10715.
95. Cai X, Carlson J, Stoicov C, et al. *Helicobacter felis* eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice. *Gastroenterology* 2005;128:1937–1952.
96. Houghton J, Stoicov C, Nomura S, et al. Gastric cancer originating from bone marrow-derived cells. *Science* 2004;306:1568–1571.
97. Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. *Cancer Cell* 2008;14:408–419.